ATE368055T1 - Monoklonale antikörper gegen den interferonrezeptor, mit neutralisierender aktivität gegen typ i-interferon - Google Patents

Monoklonale antikörper gegen den interferonrezeptor, mit neutralisierender aktivität gegen typ i-interferon

Info

Publication number
ATE368055T1
ATE368055T1 AT02028948T AT02028948T ATE368055T1 AT E368055 T1 ATE368055 T1 AT E368055T1 AT 02028948 T AT02028948 T AT 02028948T AT 02028948 T AT02028948 T AT 02028948T AT E368055 T1 ATE368055 T1 AT E368055T1
Authority
AT
Austria
Prior art keywords
interferon
monoclonal antibodies
neutralizing activity
receptor
type
Prior art date
Application number
AT02028948T
Other languages
English (en)
Inventor
Patrick Benoit
Francois Meyer
Debborah Maguire
Ivan Plavec
Michael Tovey
Original Assignee
Medisup Internat N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medisup Internat N V filed Critical Medisup Internat N V
Application granted granted Critical
Publication of ATE368055T1 publication Critical patent/ATE368055T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02028948T 1992-03-31 1993-03-30 Monoklonale antikörper gegen den interferonrezeptor, mit neutralisierender aktivität gegen typ i-interferon ATE368055T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92400902A EP0563487A1 (de) 1992-03-31 1992-03-31 Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon

Publications (1)

Publication Number Publication Date
ATE368055T1 true ATE368055T1 (de) 2007-08-15

Family

ID=8211644

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93907858T ATE241008T1 (de) 1992-03-31 1993-03-30 Monoklonale antikörper gegen den interferonrezeptor, mit neutralisierender aktivität gegen typ i-interferon
AT02028948T ATE368055T1 (de) 1992-03-31 1993-03-30 Monoklonale antikörper gegen den interferonrezeptor, mit neutralisierender aktivität gegen typ i-interferon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93907858T ATE241008T1 (de) 1992-03-31 1993-03-30 Monoklonale antikörper gegen den interferonrezeptor, mit neutralisierender aktivität gegen typ i-interferon

Country Status (18)

Country Link
US (5) US5919453A (de)
EP (3) EP0563487A1 (de)
JP (2) JP3836500B2 (de)
AT (2) ATE241008T1 (de)
AU (2) AU679909B2 (de)
BG (1) BG99141A (de)
CA (1) CA2133106C (de)
CZ (1) CZ236994A3 (de)
DE (2) DE69334158T2 (de)
DK (2) DK0633931T3 (de)
ES (2) ES2199941T3 (de)
FI (1) FI944509A (de)
HU (1) HUT69995A (de)
NO (1) NO943625L (de)
NZ (1) NZ251343A (de)
PT (2) PT633931E (de)
RU (1) RU94045826A (de)
WO (1) WO1993020187A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
WO1995007716A1 (en) * 1993-09-17 1995-03-23 Laboratoire Europeen De Biotechnologie S.A. Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
EP2236156A3 (de) * 2001-01-09 2011-01-05 Baylor Research Institute Verfahren zur Behandlung und Diagnose von Psoriasis
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US7939076B2 (en) * 2003-04-23 2011-05-10 Medarex, Inc. Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist
ES2368737T3 (es) * 2003-04-23 2011-11-21 Medarex, Inc. Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
AU2007203559B2 (en) * 2003-04-23 2010-09-02 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
LT2418220T (lt) 2003-12-10 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa antikūnai ir jų panaudojimas
AU2005250369A1 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
PT2662390T (pt) 2004-06-21 2017-10-09 Squibb & Sons Llc Anticorpos contra recetor 1 do interferão alfa e as suas utilizações
BRPI0516470A (pt) * 2004-10-07 2008-09-09 Universitot Zuerich uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase
JP5837730B2 (ja) * 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
BRPI0613306A2 (pt) * 2005-06-22 2010-12-28 Genentech Inc anticorpos isolados, polipeptìdeos imunoglobulina, anticorpo ifnar2, molécula de acido nucléico, célula hospedeira, linhagem celular, método de produção do anticorpo, composição, método para diagnosticar a presença de ifnar2, método de tratamento de uma doença e métodos
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-IFNAR1 antibodies with reduced Fc ligand affinity
KR101687032B1 (ko) 2008-05-07 2016-12-15 아고스 쎄라퓨틱스, 인코포레이티드 인간 인터페론-알파에 대한 인간화 항체
US8999340B2 (en) * 2010-03-01 2015-04-07 Alexion Pharmaceuticals, Inc. Methods for treating multiorgan, systemic degos' disease with a complement inhibitor
WO2013134146A1 (en) * 2012-03-07 2013-09-12 The Regents Of The University Of California Methods and compositions for treating viral infections by blocking type i interferon activity
US11136399B2 (en) 2016-07-14 2021-10-05 Institute Of Biophysics, Chinese Academy Of Sciences Type I interferon receptor antibody and use thereof
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
WO2020156474A1 (en) * 2019-01-31 2020-08-06 Immunecent Biotechnology, Inc. Novel anti-ifnar1 antibodies
WO2023025248A1 (zh) 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
CN115028730B (zh) * 2022-05-17 2022-11-08 诺赛联合(北京)生物医学科技有限公司 一种成体干细胞衍生的类器官制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953132A (en) 1955-10-27 1960-09-20 Baxter Laboratories Inc Parenteral solution equipment
US3066671A (en) 1959-10-27 1962-12-04 Milton J Cohen Disposable additive container
US3608550A (en) 1969-05-07 1971-09-28 Becton Dickinson Co Transfer needle assembly
BE791340A (fr) 1972-01-06 1973-03-01 Becton Dickinson Co Nouveaux procede et appareil de prelevement de culture et d'identification de micro-organismes des humeurs
US4024857A (en) 1974-12-23 1977-05-24 Becton, Dickinson And Company Micro blood collection device
US4300404A (en) 1977-12-01 1981-11-17 Becton, Dickinson And Company Liquid specimen container
US4116066A (en) 1977-12-12 1978-09-26 Becton, Dickinson And Company Specimen sampler cup
US5516515A (en) * 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
FR2653445B1 (fr) * 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2657881A1 (fr) * 1990-02-05 1991-08-09 Europ Biotechnologie Lab Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides.
IL99232A0 (en) * 1990-08-20 1992-07-15 Univ Columbia Methods for producing rna viruses from cdna
US6475983B1 (en) * 1991-04-17 2002-11-05 Medisup International N.V. Water-soluble polypeptides having a high affinity for α and β interferons
EP0563487A1 (de) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
EP0671926B1 (de) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunmodulierende peptide
JP3887011B2 (ja) * 1992-12-29 2007-02-28 ジェネンテク，インコーポレイテッド ＩＦＮ−γインヒビターによる炎症性腸疾患の処置
DK0741577T3 (da) * 1994-03-07 2003-02-17 Imperial College Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor

Also Published As

Publication number Publication date
ES2199941T3 (es) 2004-03-01
US20020055492A1 (en) 2002-05-09
DK0633931T3 (da) 2003-09-15
CZ236994A3 (en) 1995-02-15
US6787634B2 (en) 2004-09-07
US7465451B2 (en) 2008-12-16
EP1329459A2 (de) 2003-07-23
EP1329459A3 (de) 2003-09-10
JP2006089494A (ja) 2006-04-06
FI944509A (fi) 1994-11-29
ATE241008T1 (de) 2003-06-15
NO943625D0 (no) 1994-09-29
AU679909B2 (en) 1997-07-17
NZ251343A (en) 1997-07-27
ES2290241T3 (es) 2008-02-16
JP3836500B2 (ja) 2006-10-25
US7179465B2 (en) 2007-02-20
CA2133106A1 (en) 1993-10-14
PT1329459E (pt) 2007-11-07
EP0563487A1 (de) 1993-10-06
DE69334158T2 (de) 2008-04-10
US20040191840A1 (en) 2004-09-30
DK1329459T3 (da) 2007-11-26
US20070128701A1 (en) 2007-06-07
EP1329459B1 (de) 2007-07-25
US20080226647A1 (en) 2008-09-18
RU94045826A (ru) 1996-11-10
FI944509A0 (fi) 1994-09-29
AU3890793A (en) 1993-11-08
AU2349697A (en) 1997-07-24
PT633931E (pt) 2003-09-30
AU706473B2 (en) 1999-06-17
HUT69995A (en) 1995-09-28
WO1993020187A1 (en) 1993-10-14
HU9402823D0 (en) 1995-01-30
CA2133106C (en) 2009-06-30
US5919453A (en) 1999-07-06
EP0633931B1 (de) 2003-05-21
DE69334158D1 (de) 2007-09-06
NO943625L (no) 1994-11-11
JPH07505526A (ja) 1995-06-22
DE69332997T2 (de) 2004-05-19
EP0633931A1 (de) 1995-01-18
DE69332997D1 (de) 2003-06-26
BG99141A (bg) 1995-07-28

Similar Documents

Publication Publication Date Title
ATE241008T1 (de) Monoklonale antikörper gegen den interferonrezeptor, mit neutralisierender aktivität gegen typ i-interferon
ATE141329T1 (de) Rekombinante antikörper spezifisch für einen wachstumsfaktor-rezeptor
ATE305971T1 (de) Monoklonale antikörper und fv gegen das cd2 antigen
DE69839270D1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
EA199800733A1 (ru) Антагонисты рецептора il-8
DE69535243D1 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DE68929384T2 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor
ATE171472T1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
ATE175241T1 (de) Antikörper gegen alpha v beta 3 integrin
DE69431843T2 (de) Il-8 inhibitoren
CA2008817A1 (en) M-csf monoclonal antibodies that recognize a neutralizing conformational epitope
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
DE69529272T2 (de) MONOKLONALER ANTIKÖRPER GEGEN DAS HUMANE Mx-PROTEIN MxA
IT1239065B (it) Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
DE59310204D1 (de) Spezifische Antikörper gegen aktivierte Plättchen, ihre Herstellung und ihre Verwendung in Diagnose und Therapie
ATE309371T1 (de) Protein mit dnase-aktivität
DE68913872D1 (de) Monoklonale Antikörper gegen den menschlichen Epidermal-Wachstumsfaktor mit hohem Molekulargewicht.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1329459

Country of ref document: EP